Identification of potential neuromotor mechanisms of manual therapy in patients with musculoskeletal disablement

Study protocol

Identification of potential neuromotor mechanisms of manual therapy in patients with musculoskeletal disablement: rationale and description of a clinical trial

Beth E Fisher , Todd E Davenport , Kornelia Kulig and Allan D Wu

BMC Neurology 2009, 9:20 doi:10.1186/1471-2377-9-20
Published: 21 May 2009

Abstract (provisional)

Background

Many health care practitioners use a variety of hands-on treatments to improve symptoms and disablement in patients with musculoskeletal pathology. Research to date indirectly suggests a potentially broad effect of manual therapy on the neuromotor processing of functional behavior within the supraspinal central nervous system (CNS) in a manner that may be independent of modification at the level of local spinal circuits. However, the effect of treatment speed, as well as the specific mechanism and locus of CNS changes, remain unclear.

Results

We developed a placebo-controlled, randomized study to test the hypothesis that manual therapy procedures directed to the talocrural joint in individuals with post-acute ankle sprain induce a change in corticospinal excitability that is relevant to improve the performance of lower extremity functional behavior.

Conclusion

This study is designed to identify potential neuromotor changes associated with manual therapy procedures directed to the appendicular skeleton, compare the relative effect of treatment speed on potential neuromotor effects of manual therapy procedures, and determine the behavioral relevance of potential neuromotor effects of manual therapy procedures.

The complete article is available as a provisional PDF.

Proteins Underlying Devastating Brain Diseases Uncovered

ScienceDaily (May 19, 2009) — Scientists at the Wellcome Trust Sanger Institute have discovered a set of brain proteins responsible for some of the most common and devastating brain diseases. The proteins underlie epilepsy, depression, schizophrenia, bipolar disease, mental retardation and neurodegenerative diseases including Alzheimer's and Huntington's diseases.

PPARγ stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss

Neurochem Int. 2009 May 11. [Epub ahead of print]

PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss.

Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R.Department of Anatomy, Pharmacology and Forensic Medicine, University of Turin, Turin, Italy.

Pro-oxidant mitochondrial matrix-targeted ubiquinone MitoQ10 acts as anti-oxidant at retarded electron transport or proton pumping within Complex I.

Pro-oxidant mitochondrial matrix-targeted ubiquinone MitoQ10 acts as anti-oxidant at retarded electron transport or proton pumping within Complex I.


Plecitá-Hlavatá L, Jezek J, Jezek P. Department No 75, Institute of Physiology, Academy of Sciences, Vídenská 1083, Prague, Czech Republic. plecita@...

Source: Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1697-707. Epub 2009 Mar 3.
Link to this abstract: http://www.ncbi.nlm.nih.gov/pubmed/19433311

The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C–Cdh1

Nature Cell Biology Published online: 17 May 2009 doi:10.1038/ncb1881

The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C–Cdh1

Angel Herrero-Mendez1, Angeles Almeida1,2, Emilio Fernández1, Carolina Maestre1,2, Salvador Moncada3 & Juan P. Bolaños1

Departamento de Bioquimica y Biologia Molecular, Universidad de Salamanca, Instituto de Neurociencias de Castilla y Leon, 37007 Salamanca, Spain.
Unidad de Investigacion, Hospital Universitario de Salamanca, Instituto de Estudios de Ciencias de la Salud de Castilla y Leon, 37007 Salamanca, Spain.
Wolfson Institute for Biomedical Research, University College London, Gower Street, London WC1E 6BT, UK.
Correspondence to: Juan P. Bolaños1 e-mail: jbolanos@usal.es
Correspondence to: Salvador Moncada3 e-mail: s.moncada@ucl.ac.uk

Autosomal recessive cerebellar ataxias.

Presse Med. 2009 May 11. [Epub ahead of print]

Autosomal recessive cerebellar ataxias.

[Article in French]
Tranchant C, Anheim M.
Clinique neurologique, Hôpitaux universitaires, F-67091 Strasbourg Cedex, France.

Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxi

Neurogenetics. 2009 May 14. [Epub ahead of print]

Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management.
Anheim M, Fleury M, Monga B, Laugel V, Chaigne D, Rodier G, Ginglinger E, Boulay C, Courtois S, Drouot N, Fritsch M, Delaunoy JP, Stoppa-Lyonnet D, Tranchant C, Koenig M.
Département de Neurologie, Hôpital Civil, Centre Hospitalier Universitaire de Strasbourg, 1, place de l'Hôpital, 67000, Strasbourg, France, anheim@titus.u-strasbg.fr.

The biology of PGC-1α and its therapeutic potential

The biology of PGC-1α and its therapeutic potential


Christoph Handschina, b,
aBiozentrum, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
bInstitute of Physiology and Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
Available online 14 May 2009.

Ataxia de Friedreich- Friedreich's ataxia (en la atención primaria)

Aten Primaria. 2009 May 7.
Ataxia de Friedreich- Friedreich's ataxia.

[Article in Spanish]

Ortiz Uriarte R, García Ribes M, Gutiérrez VM, Sorlí JV, Valderrama Zurián FJ, Mingarro Castillo MM, Ejarque Domènech I.Grupo de trabajo semFYC Genética clínica y enfermedades raras; Centro de Salud, La Cavada, Cantabria, España.PMID: 19427070 [PubMed - as supplied by publisher]

A Study Investigating the Long-Term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia

A Study Investigating the Long-Term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia

http://www.clinicaltrials.gov/ct2/show/NCT00897221?term=friedreich

This study is not yet open for participant recruitment.
Verified by ApoPharma, May 2009
First Received: May 8, 2009 No Changes Posted
Sponsored by: ApoPharma

Information provided by: ApoPharma
ClinicalTrials.gov Identifier: NCT00897221